We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > respiratory diseases

News List

GlaxoSmithKline mulls respiratory exit to support big bet on cancer R&D fiercebiotech
November 02, 2018
GlaxoSmithKline may exit the respiratory business and pull back in other areas to commit more cash to cancer R&D, according to Axel Hoos. Hoos, GSK’s head of oncology, ...
UK’s Enterprise Therapeutics raises £29m pharmatimes
April 13, 2018
Brighton, UK-based Enterprise Therapeutics has raised £29 million to help it advance its experimental therapies for respiratory diseases.
AstraZeneca inks respiratory disease mRNA pact with Ethris fiercebiotech
August 22, 2017
AstraZeneca and Ethris are researching asthma, chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis.
AstraZeneca, MedImmune and Ethris to develop mRNA treatments for respiratory diseases pharmaceutical-technology
August 22, 2017
AstraZeneca, along with its global biologics research and development unit MedImmune, and German biotech Ethris have entered a strategic research collaboration to develop stabilised non-immunogenic modified messenger ribonucleic acid (mRNA) therapies for